High hopes are put into the use of mesenchymal stem cells (MSCs) in various approaches for tissue engineering and regenerative medicine. MSCs are derived from different tissues with only small differences in their phenotype or their differentiation potential, but higher differences in the cell yield. Since fat is easily accessible and contains a high amount of MSCs to be isolated, adipose-derived stem cells (ASCs) are very promising for clinical approaches. ASCs are not a completely homogeneous cell population. Our study was initiated to explore an easy and convenient method to reduce heterogeneity. We tested different isolation methods: (1) the standard isolation method for ASCs based on plastic attachment, (2) the standard method with an initial washing step after 60 min of adherence and (3) immunomagnetic isolation by 4 typical markers (CD49a, CD90, CD105 and CD271). Cells isolated by these methods were evaluated using quantitative PCR and flow cytometry as well as by their differentiation potential. Washing led to a significantly lower expression of desmin, smA and six2, and a higher expression of the stem cell markers nestin, oct-4 and sall-1, compared to standard isolated cells, while the immunomagnetically isolated cells showed no significant changes. All cells independent of the isolation method could be induced to differentiate into adipocytes and osteoblasts. Our study demonstrates that a simple washing step reduces heterogeneity of cultured ASCs according to PCR analysis, whereas the immunomagnetic isolation only showed minor advantages compared to the standard method, but the disadvantage of significantly lower cell yields in the primary isolates.

Keywords:
Adipose-derived stem cells, Immunomagnetic isolation, Isolation method, Mesenchymal
1.
Aslan, H., Y. Zilberman, L. Kandel, M. Liebergall, R.J. Oskouian, D. Gazit, Z. Gazit (2006) Osteogenic differentiation of noncultured immunoisolated bone marrow-derived CD105+ cells. Stem Cells 24: 1728–1737.
2.
Baer, P.C., C. Missler, J. Bereiter-Hahn, M. Brzoska, R. Schubert, S. Gauer, H. Geiger (2009) Conditioned medium from renal tubular epithelial cells initiates differentiation of human mesenchymal stem cells. Cell Prolif 42: 29–37.
3.
Banas, A., T. Teratani, Y. Yamamoto, M. Tokuhara, F. Takeshita, G. Quinn, H. Okochi, T. Ochiya (2007) Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes. Hepatology 46: 219–228.
4.
Battula, V.L., S. Treml, P.M. Bareiss, F. Gieseke, H. Roelofs, P. de Zwart, I. Muller, B. Schewe, T. Skutella, W.E. Fibbe, L. Kanz, H.J. Buhring (2009) Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1 (MSCA-1). Haematologica 9: 173–84.
5.
Brzoska, M., H. Geiger, S. Gauer, P. Baer (2005) Epithelial differentiation of human adipose tissue-derived adult stem cells. Biochem Biophys Res Commun 330: 142–150.
6.
Cao, Y., Z. Sun, L. Liao, Y. Meng, Q. Han, R.C. Zhao (2005) Human adipose tissue-derived stem cells differentiate into endothelial cells in vitro and improve postnatal neovascularization in vivo. Biochem Biophys Res Commun 332: 370–379.
7.
Chomczynski, P., N. Sacchi (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156–159.
8.
Deschaseaux, F., F. Gindraux, R. Saadi, L. Obert, D. Chalmers, P. Herve (2003) Direct selection of human bone marrow mesenchymal stem cells using an anti-CD49a antibody reveals their CD45med,low phenotype. Br J Haematol 122: 506–517.
9.
Dicker, A., K. Le Blanc, G. Astrom, V. van Harmelen, C. Gotherstrom, L. Blomqvist, P. Arner, M. Ryden (2005) Functional studies of mesenchymal stem cells derived from adult human adipose tissue. Exp Cell Res 308: 283–290.
10.
Dominici, M., K. Le Blanc, I. Mueller, I. Slaper-Cortenbach, F.C. Marini, D.S. Krause, R.J. Deans, A. Keating, D.J. Prockop, E.M. Horwitz (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315–317.
11.
Ho, A.D., W. Wagner, W. Franke (2008) Heterogeneity of mesenchymal stromal cell preparations. Cytotherapy 10: 320–330.
12.
Horn, P., S. Bork, A. Diehlmann, T. Walenda, V. Eckstein, A.D. Ho, W. Wagner (2008) Isolation of human mesenchymal stromal cells is more efficient by red blood cell lysis. Cytotherapy 10: 676–685.
13.
Jarocha, D., E. Lukasiewicz, M. Majka (2008) Adventage of mesenchymal stem cells (MSC) expansion directly from purified bone marrow CD105+ and CD271+ cells. Folia Histochem Cytobiol 46: 307–314.
14.
Jurgens, W.J., M.J. Oedayrajsingh-Varma, M.N. Helder, B. Zandiehdoulabi, T.E. Schouten, D.J. Kuik, M.J. Ritt, F.J. van Milligen (2008) Effect of tissue-harvesting site on yield of stem cells derived from adipose tissue: implications for cell-based therapies. Cell Tissue Res 332: 415–426.
15.
Kern, S., H. Eichler, J. Stoeve, H. Kluter, K. Bieback (2006) Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 24: 1294–1301.
16.
Krampera, M., A. Pasini, G. Pizzolo, L. Cosmi, S. Romagnani, F. Annunziato (2006) Regenerative and immunomodulatory potential of mesenchymal stem cells. Curr Opin Pharmacol 6: 435–441.
17.
Lange, C., H. Bruns, D. Kluth, A.R. Zander, H.C. Fiegel (2006) Hepatocytic differentiation of mesenchymal stem cells in cocultures with fetal liver cells. World J Gastroenterol 12: 2394–2397.
18.
Lee, W.C., J.P. Rubin, K.G. Marra (2006) Regulation of alpha-smooth muscle actin protein expression in adipose-derived stem cells. Cells Tissues Organs 183: 80–86.
19.
Lin, G., M. Garcia, H. Ning, L. Banie, Y.L. Guo, T.F. Lue, C.S. Lin (2008) Defining stem and progenitor cells within adipose tissue. Stem Cells Dev 17: 1053–1063.
20.
Mageed, A.S., D.W. Pietryga, D.H. DeHeer, R.A. West (2007) Isolation of large numbers of mesenchymal stem cells from the washings of bone marrow collection bags: characterization of fresh mesenchymal stem cells. Transplantation 83: 1019–1026.
21.
Mitchell, J.B., K. McIntosh, S. Zvonic, S. Garretta, Z.E. Floyd, A. Kloster, Y. Di Halvorsen, R.W. Storms, B. Goh, G. Kilroy, X.Y. Wu, J.M. Gimble (2006) Immunophenotype of human adipose-derived cells: temporal changes in stromal-associated and stem cell-associated markers. Stem Cells 24: 376–385.
22.
Nishinakamura, R. (2008) Stem cells in the embryonic kidney. Kidney Int 73: 913–917.
23.
Oedayrajsingh-Varma, M.J., S.M. van Ham, M. Knippenberg, M.N. Helder, J. Klein-Nulend, T.E. Schouten, M.J.P.F. Ritt, F.J. van Milligen (2006) Adipose tissue-derived mesenchymal stem cell yield and growth characteristics are affected by the tissue-harvesting procedure. Cytotherapy 8: 166–177.
24.
Pfaffl, M.W. (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
25.
Rider, D.A., T. Nalathamby, V. Nurcombe, S.M. Cool (2007) Selection using the alpha-1 integrin (CD49a) enhances the multipotentiality of the mesenchymal stem cell population from heterogeneous bone marrow stromal cells. J Mol Histol 38: 449–458.
26.
Suga, H., D. Matsumoto, H. Eto, K. Inoue, N. Aoi, H. Kato, J. Araki, K. Yoshimura (2009) Functional implications of CD34 expression in human adipose-derived stem/progenitor cells. Stem Cells Dev 18: 1201–1210.
27.
Self, M., O.V. Lagutin, B. Bowling, J. Hendrix, Y. Cai, G.R. Dressler, G. Oliver (2006) Six2 is required for suppression of nephrogenesis and progenitor renewal in the developing kidney. EMBO J 25: 5214–5228.
28.
Varma, M.J., R.G. Breuls, T.E. Schouten, W.J. Jurgens, H.J. Bontkes, G.J. Schuurhuis, S.M. van Ham, F.J. van Milligen (2007) Phenotypical and functional characterization of freshly isolated adipose tissue-derived stem cells. Stem Cells Dev 16: 91–104.
29.
Wagner, W., F. Wein, A. Seckinger, M. Frankhauser, U. Wirkner, U. Krause, J. Blake, C. Schwager, V. Eckstein, W. Ansorge, A.D. Ho (2005) Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol 33: 1402–1416.
30.
Wagner, W., R.E. Feldmann, A. Seckinger, M.H. Maurer, F. Wein, J. Blake, U. Krause, A. Kalenka, H.F. Burgers, R. Saffrich, P. Wuchter, W. Kuschinsky, A.D. Ho (2006) The heterogeneity of human mesenchymal stem cell preparations – evidence from simultaneous analysis of proteomes and transcriptomes. Exp Hematol 34: 536–548.
31.
Wong, C.Y., S.K. Cheong, P.L. Mok, C.F. Leong (2008) Differentiation of human mesenchymal stem cells into mesangial cells in post-glomerular injury murine model. Pathology 40: 52–57.
32.
Yoshimura, K., T. Shigeura, D. Matsumoto, T. Sato, Y. Takaki, E. Aiba-Kojima, K. Sato, K. Inoue, T. Nagase, I. Koshima, K. Gonda (2006) Characterization of freshly isolated and cultured cells derived from the fatty and fluid portions of liposuction aspirates. J Cell Physiol 208: 64–76.
33.
Zuk, P.A., M. Zhu, H. Mizuno, J. Huang, J.W. Futrell, A.J. Katz, P. Benhaim, H.P. Lorenz, M.H. Hedrick (2001) Multilineage cells from human adipose tissue: Implications for cell-based therapies. Tissue Eng 7: 211–228.
34.
Zuk, P.A., M. Zhu, P. Ashjian, D.A. De Ugarte, J.I. Huang, H. Mizuno, Z.C. Alfonso, J.K. Fraser, P. Benhaim, M.H. Hedrick (2002) Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 13: 4279–4295.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.